ABT-737

For research use only.

Catalog No.S1002

253 publications

ABT-737 Chemical Structure

CAS No. 852808-04-9

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. ABT-737 induces mitochondrial pathway apoptosis and mitophagy. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 384 In stock
USD 120 In stock
USD 200 In stock
USD 570 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's ABT-737 has been cited by 253 publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. ABT-737 induces mitochondrial pathway apoptosis and mitophagy. Phase 2.
Features First-generation inhibitor of anti-apoptotic Bcl-2 proteins.
Targets
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
Bcl-B [1]
(Cell-free assay)
30.3 nM(EC50) 78.7 nM(EC50) 197.8 nM(EC50) 1.82 μM(EC50)
In vitro

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. [1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. [2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. [3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. [4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OCI-Ly1  Ml\LR4VtdCCYaXHibYxqfHliQYPzZZk> MYiyOVAhdk4EoB?= NHK0[lA4OiCq MonpSG1UVw>? NHPROHJk[XW|ZXSgPVcmKGyxc4Ogc4YhfmmjYnnsbZR6KGmwIHPlcIx{KHS{YX7z[oVkfGWmIIfpeIghSkOONjDzbXJPSQ>? NW\Sb5BvOjZ4NUeyPFg>
KG1a M1m2cmNmdGxiVnnhZoltcXS7IFHzd4F6 NYCweYo{OC1zMDFOwG0> MXeyOEBp MWfEUXNQ NELJW3lKSzVyPUeuOlgh|ryPLDDk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Ml\SNlY2PTJ5MUK=
Kasumi-1 M4q4eWNmdGxiVnnhZoltcXS7IFHzd4F6 NUf0eFlUOC1zMDFOwG0> M3TnPFI1KGh? MUDEUXNQ MV7JR|UxRTRwOEeg{txONCCmZXPy[YF{\XNiY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MnP0NlY2PTJ5MUK=
KG1a NXzWWm95SXCxcITvd4l{KEG|c3H5 NVXSU2NrOC1zMDFOwG0> Mn\TNlQhcA>? MlLaSG1UVw>? Mn;3bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MUGyOlU2OjdzMh?=
Kasumi-1 NF\uOHhCeG:ydH;zbZMhSXO|YYm= MVSwMVExKM7:TR?= MXOyOEBp Mmq2SG1UVw>? MYTpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NWTDfWt{OjZ3NUK3NVI>
MC-3  MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYO1M|ExNzJyIN88US=> NEjv[3EzPCCq NF:2c5NFVVOR M4faW4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MWeyOlQ1PzZzNR?=
HN22  Mm\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\vNk42NzdwNT:yNk42KM7:TR?= Ml\zNlQhcA>? MlmzSG1UVw>? MYLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NF7nO|EzPjR2N{[xOS=>
MC-3  MUXBdI9xfG:|aYOgRZN{[Xl? NXnOO5c1PS9zMD:yNEDPxE1? NHvmUWozPCCq NXrwXo5jTE2VTx?= NVHZOmxscW6mdXPld{Bk[XOyYYPlMY1m\GmjdHXkJIFxd3C2b4Ppdy=> NUPsUIRvOjZ2NEe2NVU>
HN22  M{nBemFxd3C2b4Ppd{BCe3OjeR?= MV:yMlUwPy53L{KyMlUh|ryP MYKyOEBp MmDvSG1UVw>? MV3pcoR2[2W|IHPhd5Bie2VvbXXkbYF1\WRiYYDvdJRwe2m| MX[yOlQ1PzZzNR?=
MOLT-4 M{f5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV24dGdROTBvNUCwNEBvVQ>? MVy3NkBp Ml7QSG1UVw>? M2Dwe2lEPTB;MD6xPVgh|ryP M4\nOVI3Ozl{M{Oy
RS4;11 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVy3TZNQOTBvNUCwNEBvVQ>? NUfuZlRnPzJiaB?= Ml7QSG1UVw>? M{TmNWlEPTB;MD6wNFIh|ryP M{OxNFI3Ozl{M{Oy
JURKAT M3;SSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWxNE02ODByIH7N M{LsXlczKGh? NGTXT21FVVOR MVjJR|UxRTZ4IN88US=> NHrlSm8zPjN7MkOzNi=>
CEM R NUDpPXJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlqzNVAuPTByMDDuUS=> MWW3NkBp NUTwVlh3TE2VTx?= NE\6VG1KSzVyPUWuOEDPxE1? M4iyNVI3Ozl{M{Oy
CEM S NGPyXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{P6bFExNTVyMECgcm0> MoDGO|IhcA>? M1\yS2ROW09? NEPNNZBKSzVyPUGyMlEh|ryP MkC0NlY{QTJ|M{K=
MOLT-4 NHjtZ4ZCeG:ydH;zbZMhSXO|YYm= M1XWelExNTFyMECgcm0> M1[zOFI1KGh? NXq4fWZxTE2VTx?= M{Poc4NifXOnczD0bIUh[2ynYY\h[4Uhd2ZiQnPsMVIh[W6mIITo[UBld3ewcnXneYxifGmxbjDv[kBD[2xveFygZY5lKE2lbD2x M3[5cFI3Ozl{M{Oy
CEM S MWXBdI9xfG:|aYOgRZN{[Xl? NUHF[HhROTBvMUCwNEBvVQ>? MY[yOEBp Mm\BSG1UVw>? NFj6cmpk[XW|ZYOgeIhmKGOuZXH2ZYdmKG:oIFLjcE0zKGGwZDD0bIUh\G:5boLl[5Vt[XSrb36gc4YhSmOuLYjMJIFv\CCPY3ytNS=> NGfNZ5YzPjN7MkOzNi=>
JURKAT NHqwcXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPzXIlwOTByLUGwNFAhdk1? NHHrdow1QCCq NF;oRZNFVVOR NWDkSG44UUN3ME25OVXDuTlwMzDuUS=> Ml;1NlYyPzJ{Nkm=
LOUCY M4jLUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7RNVAxNTFyMECgcm0> NYP4[ml5PDhiaB?= NFvSWI9FVVOR NEXqZ5RKSzVyPUOyMljDuTFyLkmgcm0> NF:zcmozPjF5MkK2PS=>
WM-115 MY\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmDRNVAxyqCwTR?= NEHFdFI4OiCq Mlq3[Y5p[W6lZYOgZ5Vz[3WvaX6tbY5lfWOnZDDhcpRqNXO3co\peoFtyqB? M2LsOlI3OTF4N{e2
B16 NUDWe2FbS2WubDDWbYFjcWyrdImgRZN{[Xl? NIjKSW0yODEEoH7N NWP5VpJ3PzJiaB?= Mnj6[Y5p[W6lZYOgZ5Vz[3WvaX6tbY5lfWOnZDDhcpRqNXO3co\peoFtyqB? M3zHO|I3OTF4N{e2
HL-60  M1HEfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;NVWU4OiCq NF3qZZZKSzVywrC9JFExNjdibl2= M2DVelI3ODR3NkC5
MOLM-13  M13ycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13E[lczKGh? MnH2TWM2OMLiPTCyO{46KG6P M1vmUVI3ODR3NkC5
OCI-AML3 M1Xlfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnyUYE4OiCq MnfWTWM2OMLiPTCxPVUxKG6P NYO2T4lpOjZyNEW2NFk>
BCWM.1 NX3RepBmSXCxcITvd4l{KEG|c3H5 MYOwMVEvPiEQvF2= MUSyOEBp MX3pcoR2[2W|IHPlcIwh[XCxcITvd4l{ NEjMWGQzPTh7M{K5NC=>
MWCL-1 MlS1RZBweHSxc3nzJGF{e2G7 NYT2PIN7OC1zLk[g{txO NIjZUnkzPCCq NYH4fIdCcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= Mm\NNlU5QTN{OUC=
MM.1s NInvTHNCeG:ydH;zbZMhSXO|YYm= NFTrOm8xNTFwNjFOwG0> NYC2T5JPOjRiaB?= Mo\rbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MnjXNlU5QTN{OUC=
HCT116 NEnEXlRHfW6ldHnvckBCe3OjeR?= MUOzM|ExKM7:TR?= NVuz[Zh6OTMEoHlCpC=> MUPEUXNQ MYrpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6gUGM{Si2LSTDjc453\XK|aX;uJIFv\CCVUWPUUVEh\GWpcnHkZZRqd25? Mn7NNlU4OTVyMki=
HCT116 BAX BAK1 DKO NH64NHdHfW6ldHnvckBCe3OjeR?= M1;Oe|MwOTBizszN M4LndVEzyqCqwrC= NUTSPGhyTE2VTx?= MVnpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6gUGM{Si2LSTDjc453\XK|aX;uJIFv\CCVUWPUUVEh\GWpcnHkZZRqd25? NIfQOHUzPTdzNUCyPC=>
HCT116 Ml7pSpVv[3Srb36gRZN{[Xl? MYmxNEDPxE1? MWWxNuKhcMLi MUXEUXNQ MXrpcoNz\WG|ZYOgS2ZRNUyFM1KgdJVv[3Sj MlPnNlU4OTVyMki=
HCT116 BAX BAK1 DKO M1vYdWZ2dmO2aX;uJGF{e2G7 M{nOT|ExKM7:TR?= M4Szb|EzyqCqwrC= MkX0SG1UVw>? NGD1SHFqdmO{ZXHz[ZMhT0[SLVzDN2IheHWwY4Th NYHkXnN5OjV5MUWwNlg>
HCT116 NHK5XpFCfXSxcHjh[5khSXO|YYm= NIXlSGIyOCEQvF2= NWDhRZkyOTMEoHlCpC=> MXnEUXNQ M3L1TYlv\HWlZYOgZUBkd22ybHX0[UBifXSxcHjh[4lkKHKnc4DvcpNm MofVNlU4OTVyMki=
HCT116 BAX BAK1 DKO NEfnVGpCfXSxcHjh[5khSXO|YYm= NVr4e|BHOTBizszN NUfaeos1OTMEoHlCpC=> M{TwcWROW09? MkXybY5lfWOnczDhJINwdXCuZYTlJIF2fG:yaHHnbYMhemW|cH;ud4U> M1jrcVI2PzF3MEK4
U937 M3PtN2Fxd3C2b4Ppd{BCe3OjeR?= MYewMlEzPS1{IN88US=> MYeyOEBp NGDkd5FmdmijbnPld{BFUEFxWD2xNU1qdmS3Y3XkJIFxd3C2b4Ppdy=> Mn7iNlU4OTRyMkS=
U937  MoXFRZBweHSxc3nzJGF{e2G7 MYiwMlUh|ryP Mk\INlQhcA>? M4XO[oVvcGGwY3XzJINt\WG4YXflJI9nKFCDUmCgZY5lKGOjc4Dhd4UuOyCjczD3[YxtKGG|IF7vfIEhdGW4ZXy= NH;Yb5EzPTdzNECyOC=>
HL-60 AAA-Bcl-2 MVfBdI9xfG:|aYOgRZN{[Xl? M3rCOFAuPSEQvF2= M3jqfVQ5KGh? NWTLcppqUUN3ME2wMlg4KM7:bf-8kIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NWTHeIxPOjV5MUG0OlA>
HL-60 EEE-Bcl-2 MVzBdI9xfG:|aYOgRZN{[Xl? MYewMVUh|ryP MYK0PEBp NUS2NFFmUUN3ME21JO69de,:jDDpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NVXs[JBlOjV5MUG0OlA>
U87 NXm5TpUxTnWwY4Tpc44hSXO|YYm= M{HNZlUxKM7:TR?= NX73bJFnOjRiaB?= NVmydoNZemWmdXPld{B1cGVibWLORUBmgHC{ZYPzbY9vKGyndnXsd{Bw\iCPTWCtNkwhVU2SLUG0JIFv\CCEY3ytNi=> NEP5V3ozPTZ4N{[2Ny=>
K562 NVW4U|VbS2WubDDWbYFjcWyrdImgRZN{[Xl? M{D2PVEuOTBizszN NUTJNIxZPDhiaB?= MUHEUXNQ M{LLfWlEPTB;Mk[uO{DPxE1? MW[yOVU6PjV4MR?=
K562/Mcl -1-IRESBim MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnGwTWM2OD17LkOg{txO NUTmXnB3OjV3M{W5NFA>
K562/Bcl- 2-IRESBim MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\DRmM2UUN3ME2wMlM2KM7:TR?= M{XUOVI2PTN3OUCw
Jurkat MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwNk[g{txO MYOyOVU{PTlyMB?=
JurkatΔBak MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRjVyIN88US=> NIHtPJgzPTV|NUmwNC=>
HL60/VCR NXXZZVg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfrSJVKSzVyPkGwNEDPxE1? Ml;CNlU2OzV7MEC=
Kasumi-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPJTWM2OD1yLkCxJO69VQ>? MXuyOVU{PTlyMB?=
Kasumi-1/ABT MnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDEbpFKSzVyPUCuOVEh|ryP NWKwcYNmOjV3M{W5NFA>
THP-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFW4eZVKSzVyPUGuNlch|ryP MVKyOVU{PTlyMB?=
U937 M2j1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrRWZZLUUN3ME21MlI6KM7:TR?= MnTtNlU2OzV7MEC=
C1498 NYqzdm1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjoUYFKSzVyPU[uNVMh|ryP NHj0WFczPTV|NUmwNC=>
RPMI 8226 NV;0XHhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwMkWg{txO MYiyOVU{PTlyMB?=
MM.1S NVnVR5J1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPFTWM2OD1yLkSwJO69VQ>? M1XucVI2PTN3OUCw
NCI-H929 MljaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTF3LkKxJO69VQ>? MoH4NlU2OzV7MEC=
U266 NVzMWlR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwNkig{txO MXSyOVU{PTlyMB?=
MCF-7 MoO2R4VtdCCYaXHibYxqfHliQYPzZZk> NXmxTlFCPSEQvF2= Moi5OFghcA>? NYO4WXRjTE2VTx?= MY\lcohidmOnczD0bIUhe2Wwc3n0bZZqfHlidH:gc5IhemGmaXH0bY9v M{L6SFI2PDB7MUK0
MCF-7 NYLodItPSXCxcITvd4l{KEG|c3H5 MYC1JO69VQ>? NIrnOVE1NzJ2L{S4JIg> NYHJTmd4TE2VTx?= MV7pcoNz\WG|ZYOgeIhmKGOuZXH2[YQhWEGUUB?= MVWyOVQxQTF{NB?=
MCF-7 MkjVSpVv[3Srb36gRZN{[Xl? NUPtR4ZXPSEQvF2= NGr0SmUzPCCq M1;BbGROW09? MWXlcohidmOnczD0bIVt\X[nbDDv[kBO[2xvMTDlfJBz\XO|aX;uxsA> MoXENlU1ODlzMkS=
MDA-MB 231  MWjGeY5kfGmxbjDBd5NigQ>? M1XBbFUh|ryP NFm1NIMzPCCq NEDjTm9FVVOR M2fvdIVvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>? MWCyOVQxQTF{NB?=
ZR-75-1  MYHGeY5kfGmxbjDBd5NigQ>? NFT1bGI2KM7:TR?= Mm\SNlQhcA>? MlrISG1UVw>? Monr[Y5p[W6lZYOgeIhmdGW4ZXygc4YhVWOuLUGg[ZhxemW|c3nvcuKh MmfWNlU1ODlzMkS=
A549 NXy5eVlwS2WubDDWbYFjcWyrdImgRZN{[Xl? MWOwMVIxKM7:TR?= MY[3NkBp NEDJdWVFVVOR M3vxe4Rm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5? MkLqNlU{QDh5NkK=
H1299 M4HDUGNmdGxiVnnhZoltcXS7IFHzd4F6 NUnBTHBmOC1{MDFOwG0> NWjyXox2PzJiaB?= NUH1cnFPTE2VTx?= M2q3RYRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5? M4PVVVI2Ozh6N{[y
HO-8910 M1LCc2NmdGxiVnnhZoltcXS7IFHzd4F6 MVGwMVIxKM7:TR?= MlzhO|IhcA>? MYDEUXNQ NXPlS|E3\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?= NEjyN3EzPTN6OEe2Ni=>
HT-29 MX7D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1PncFAuOjBizszN MXu3NkBp NWHpdZg5TE2VTx?= M2f5cYRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5? NYPsV|RGOjV|OEi3OlI>
HCT-116 MUnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MnzxNE0zOCEQvF2= NFHnZog4OiCq MWfEUXNQ MXLk[YNz\WG|ZYOgeIhmKGOnbHygd5Vzfmm4YXygbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKgZ49u[mmwZXSge4l1cCCjc4Dpdolv Mo\PNlU{QDh5NkK=
A549 NV;UN|lwSXCxcITvd4l{KEG|c3H5 MUCyNEDPxE1? NWL4OGtPPDhiaB?= MXLEUXNQ NIjuU2xqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIgh[XOyaYLpci=> M3LqdlI2Ozh6N{[y
H1299 NUe4ephKSXCxcITvd4l{KEG|c3H5 MlXsNlAh|ryP NY\3cFlEPDhiaB?= M3XyWWROW09? M13NOYlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEBie3Crcnnu MYOyOVM5QDd4Mh?=
Sc-1 M336fWNmdGxiVnnhZoltcXS7IFHzd4F6 MWewMlAxODFvMTFOwG0> M1PO[lk3KGh? NIn2cVBl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M17zO|I2Ozd|NUC4
OcI-LY18 MYTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NVT2UWREOC5yMECxMVEh|ryP Mn7uPVYhcA>? M4jsfoRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NH;NO2czPTN5M{WwPC=>
RL  M{\YOWNmdGxiVnnhZoltcXS7IFHzd4F6 NGTpSXUxNjByMEGtNUDPxE1? NHOyR4g6PiCq NF3BU2ll\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NEPTNYozPTN5M{WwPC=>
RKO NYTOb3RkS2WubDDWbYFjcWyrdImgRZN{[Xl? NFu3eoUxNTFyIN88US=> M13DclI16oDLaNMg NWHRS3lvTE2VTx?= NWXIbWh5UUN3ME9ihKkzPeLCidM1US=> NWHKOXMxOjV|MESzPFM>
Caco-2 MXPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHu3[5UxNTFyIN88US=> NH7jTXczPOLCiXlCpC=> NXvZcFZNTE2VTx?= NULCVVRmUUN3ME2xPU446oDLwsXN NWnTUmNJOjV|MESzPFM>
DLD1 M1LzT2NmdGxiVnnhZoltcXS7IFHzd4F6 MmrSNE0yOCEQvF2= MnPZNlTjiImqwrC= MX7EUXNQ MWDJR|UxRTF6Lke45qCKyrWP MmL2NlU{ODR|OEO=
LS411N MXzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NVHkOYVSOC1zMDFOwG0> M{m5S|I16oDLaNMg M4ntVGROW09? MVzJR|UxRTFzLkS35qCKyrWP NEH6c|QzPTNyNEO4Ny=>
SW620 NVK0WYtDS2WubDDWbYFjcWyrdImgRZN{[Xl? MV6wMVExKM7:TR?= NVq2O4ViOjUkgJnoxsA> MoOzSG1UVw>? NYrob4JmUUN3ME2xNk4zPOLCidM1US=> MlfhNlU{ODR|OEO=
HCT116 NYHoNW1HS2WubDDWbYFjcWyrdImgRZN{[Xl? M3zyXFAuOTBizszN NWDBbYpSOjUkgJnoxsA> NVf1cJZWTE2VTx?= M2DoNmlEPTB;MkCuOFnjiIoEtV2= M{jTUVI2OzB2M{iz
HaCaT M{KzPWNmdGxiVnnhZoltcXS7IFHzd4F6 M4G1RVAvOS9zL{GwJO69VQ>? M{fUcFI1KGh? NXnzcmp3TE2VTx?= M2jaWIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NUXVU|VXOjV{MUC3PVU>
A5-RT3 NVzPTFVsS2WubDDWbYFjcWyrdImgRZN{[Xl? MXOwMlEwOS9zMDFOwG0> NH;mbWwzPCCq MmrlSG1UVw>? MWXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NI\BUVYzPTJzMEe5OS=>
HaCaT Mmm2SpVv[3Srb36gRZN{[Xl? M13uTFEx6oDLzszN M4KwZ|I1NzR6IHi= M1jn[mROW09? MnvXbY5lfWOnczDNUXAh[W6mIFTORUBnemGpbXXueIF1cW:w MWKyOVIyODd7NR?=
A5-RT3 M125SmZ2dmO2aX;uJGF{e2G7 MYexNQKBkc7:TR?= M322flI1NzR6IHi= MXTEUXNQ Ml3wbY5lfWOnczDNUXAh[W6mIFTORUBnemGpbXXueIF1cW:w NYK3bGpFOjV{MUC3PVU>
A5-RT3 M2XPVmZ2dmO2aX;uJGF{e2G7 NHfJRoQ2KM7:TR?= MY[2JIg> NI\RRVdFVVOR NIX0XVVqdmS3Y3XzJJRp\SC{ZXzlZZNmKG:oIH3peI9kcG:wZILpZYwheHKxdHXpcpMh[W6mIILl[JVk\XNiY3zvco9o\W6rYzDzeZJ3cX[jbDDpckBiKGOjc4Dhd4UucW6mZYDlcoRmdnRibXHucoVz NYLtU2lEOjV{MUC3PVU>
U266 NGjPTllHfW6ldHnvckBCe3OjeR?= NF;TXZY2ODBxN{WwJI5O M4rNSVI1NzR6IHi= NXy3OpBuTE2VTx?= MVnkc5dvemWpdXzheIV{KEKrbTygdJJqdmOrcHHscJkhfGinIFXMJIl{d2[xcn2= M{LuSVI2OjB6OEi4
RPMI8226 NFPne5ZHfW6ldHnvckBCe3OjeR?= NVHIeGc4PTByL{e1NEBvVQ>? NGmyeoMzPC92ODDo M4H6N2ROW09? NILybVVld3ewcnXneYxifGW|IFLpcUwheHKrbnPpdIFtdHlidHjlJGVNKGm|b3\vdo0> M37hW|I2OjB6OEi4
MM.1S M37QW2Z2dmO2aX;uJGF{e2G7 M{jyTlUxOC95NUCgcm0> MoTjNlQwPDhiaB?= MojrSG1UVw>? M2mzVYRwf26{ZXf1cIF1\XNiQnntMEBxemmwY3nwZYxtgSC2aHWgSWwhcXOxZn;ycS=> M4fKWVI2OjB6OEi4
Clone A NIDOeFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;afpVKOC5{4pETOlAh|ryP NYHv[Zo4PzJiaB?= Mn\OSG1UVw>? M2D5[mlEPTB;Nz61JO69VQ>? M3rPVlI2OjB6OEiy
CX-1 NVnUd2VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYOwMlLjiJN4MDFOwG0> MUG3NkBp MVLEUXNQ NH7rT5lKSzVyPUGuPEDPxE1? MVWyOVIxQDh6Mh?=
LS174T M17Pc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\qPVNMOC5{4pETOlAh|ryP NITRUmE4OiCq MYXEUXNQ NHTub2dKSzVyPUG4MlMh|ryP MnXiNlUzODh6OEK=
HT29 NFrKTpdCeG:ydH;zbZMhSXO|YYm= NVf5SZNWOS93L{GwJO69VQ>? M{jLb|Q5KGh? NFHiZlJk[XW|ZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M2jrWlI2OTl{MUi4
SW480 M3;ySWFxd3C2b4Ppd{BCe3OjeR?= NX;Gbo5wOS93L{GwJO69VQ>? M3PjdlQ5KGh? MXnjZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MXeyOVE6OjF6OB?=
Colo205 NYDuUpRZSXCxcITvd4l{KEG|c3H5 MXKxM|UwOTBizszN MVu0PEBp M{HPRoNifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M1jMRVI2OTl{MUi4
Caco2 NUnLWFd6SXCxcITvd4l{KEG|c3H5 M2XzN|EwPS9zMDFOwG0> NXHkc|d6PDhiaB?= M3fTS4NifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M4TkUVI2OTl{MUi4
PCI-13 MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUO3NkBp NFGxNIFFVVOR MlH3S2k2OD1zNTFCtUAyNjhizszN NXfRV3pWOjVzM{mzPFc>
PCI-15B MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELhOI84OiCq NXXu[2xmTE2VTx?= MlHwS2k2OD1zMTFCtUA1NjVizszN NYTwWYl7OjVzM{mzPFc>
UM-SCC22B MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LBWVczKGh? NYHsTZVDTE2VTx?= MV3HTVUxRTF7INMxJFIvQSEQvF2= M2\iSFI2OTN7M{i3
UM-SCC47 NVPQVW1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFn5VVA4OiCq MVLEUXNQ MUDHTVUxRTF7INMxJFEzNjNizszN MXiyOVE{QTN6Nx?=
93-VU-147T NEO2fGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYC3NkBp NWH3VHZqTE2VTx?= NHrofYJIUTVyPUSuN{DDuSB|LkWg{txO MnuxNlUyOzl|OEe=
UD-SCC2 M4fzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITF[mg4OiCq MmLHSG1UVw>? NIXITGJIUTVyPUK4JOKyKDJwOTFOwG0> M{PGXVI2OTN7M{i3
UPCI:SCC90 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2WwVVczKGh? Mnm5SG1UVw>? MoLvS2k2OD14Lk[gxtEhOS53IN88US=> MknNNlUyOzl|OEe=
RPMI-8226  NUXtb4xpS2WubDDWbYFjcWyrdImgRZN{[Xl? M1nhZlEzPS9{NUCvOVAxKG6P NUjXPJpbPDiqwrC= Mnr0SG1UVw>? M1X6W4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MWSyOVAxQDJyMh?=
OPM-2  NVrBNoJxS2WubDDWbYFjcWyrdImgRZN{[Xl? MnTGNVI2NzJ3MD:1NFAhdk1? NXf0boduPDiqwrC= NHLLOoxFVVOR MnTn[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NHTm[2YzPTByOEKwNi=>
RPMI-8226  NHr4SIVCeG:ydH;zbZMhSXO|YYm= NG\udYMyOjVxMkWwM|UxOCCwTR?= NF6wdnM1QGkEoB?= MYLEUXNQ NGiwfZpqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ Mnv5NlUxODh{MEK=
OPM-2  NUnicnh2SXCxcITvd4l{KEG|c3H5 MUWxNlUwOjVyL{WwNEBvVQ>? NF3Le3M1QGkEoB?= M37XUGROW09? MoP1bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mn7tNlUxODh{MEK=
COG-LL-319 M{P6WmZ2dmO2aX;uJGF{e2G7 NULEdXhyOTByIH7N MUixM|MwPiCq MUjEUXNQ M2ri[Ilv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgUYNtNTFiY3zlZZZi\2V? NYPiXFVJOjR7NUG0O|I>
RS4;11 NVq5d201TnWwY4Tpc44hSXO|YYm= MUCxNFAhdk1? MV:xM|MwPiCq Mmi4SG1UVw>? M2DkW4lv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgUYNtNTFiY3zlZZZi\2V? M1\Ke|I1QTVzNEey

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
PARP / c-PARP / cleaved caspase 3 ; 

PubMed: 21393866     


H146 cells were preincubated in normoxia or hypoxia (1% O2) for 18 hours prior to treatment with ABT-737 (89.1 nM ), after which cells were harvested for protein analysis by Western blot. 

Hif-1a; 

PubMed: 22006676     


Representative western blots for HIF-1α, PARP and cleaved caspase 3 in response to 24-72 hr exposure to ABT-737 in varying concentration in normoxia and hypoxia in 4 neuroblastoma cell lines. Actin is shown as a loading control. Blots are representative of 3 independent experiments.

γ-H2AX / p-ATM; 

PubMed: 21084274     


Induction of γ-H2AX and p-ATM by ABT-737. Cells were treated with 10 µmol/L ABT-737 for 24 hours and then maintained in fresh media for 1 or 2 more days prior to Western blot analysis.

21393866 22006676 21084274
Immunofluorescence
cytochrome C; 

PubMed: 26447615     


Immunocytochemistry revealed the release of mitochondrial cytochrome c (green) into the cytoplasm after ABT-737 exposure (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field.

Bax; 

PubMed: 26447615     


Immunocytochemistry revealed the mitochondrial translocation of Bax from the cytoplasm after ABT-737 treatment (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field C. To assess whether ABT-737 treatment has an effect on the dimerization of Bax, the levels of dimeric Bax were measured with or without ABT-737 treatment in MC-3 and HN22 cells.

Bim; 

PubMed: 26447615     


Immunocytochemistry revealed the mitochondrial translocation of Bim from the cytoplasm after ABT-737 treatment (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field.

AIF; 

PubMed: 25034785     


localization of apoptosis inducing factor (AIF) in LCSC pre-stained with Mitotracker Red and untreated or treated with 500 nM ABT-737 for 48 h. Magnification × 60, zoom × 3, bar 20 μm. 

p65 ; 

PubMed: 28846096     


BCL-xL dependent SVEC cells were treated with ABT-737 (10 μM) +/- Q-VD-Oph (30 μM) for 1 h, immunostained for p65 and analysed by confocal microscopy. TNF (20 ng/ml) was used as positive control for p65 nuclear translocation. Scale bar represents 30μM. Representative images from three independent experiments.

26447615 25034785 28846096
Growth inhibition assay
Cell viability; 

PubMed: 22311987     


Stably transfected K562 cells were treated with increasing concentrations of ABT-737, obatoclax, or maritoclax for 24 h. Cell viability was determined by measuring intracellular ATP levels with the CellTiter Glo assay.

22311987
ELISA
IL-6 / IL-8; 

PubMed: 21084274     


The secretion of IL-6 and IL-8 in PV-10 cells treated with DMSO, ABT-737 or enantiomer for 24 hours was determined by ELISA.

21084274
In vivo In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. [1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. [2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. [5]

Protocol

Kinase Assay:

[1]

- Collapse

Fluorescence polarization assays:

Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
Cell Research:

[4]

- Collapse
  • Cell lines: SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114
  • Concentrations: 0.001-10 μM
  • Incubation Time: 48 hours
  • Method:

    SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells
  • Dosages: 20 and 30 mg/kg
  • Administration: For intraperitoneal (i.p.) every day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (122.93 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2%DMSO+40%PEG300+5%Tween80+53%ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 813.43
Formula

C42H45ClN6O5S2

CAS No. 852808-04-9
Storage powder
in solvent
Synonyms N/A
Smiles CN(C)CCC(CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What’s the recommended method about reconstitution of the compound for in vivo animal study?

  • Answer:

    For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy ABT-737 | ABT-737 supplier | purchase ABT-737 | ABT-737 cost | ABT-737 manufacturer | order ABT-737 | ABT-737 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID